<DOC>
	<DOCNO>NCT00947193</DOCNO>
	<brief_summary>Hemophilia A ( HA ) hemophilia B ( HB ) inherit bleed disorder cause mutation gene factor VIII ( FVIII ) factor IX ( FIX ) , respectively . These protein essential blood clotting . The lack FVIII/FIX produce bleed episode cause damage bone , muscle , joint , tissue . A specific type mutation , call nonsense ( premature stop codon ) mutation , cause disease approximately 10-30 % patient hemophilia result severe manifestation . Ataluren ( PTC124 ) orally deliver , investigational drug act overcome effect premature stop codon , potentially enable production functional FVIII/FIX . This study Phase 2a trial evaluate safety efficacy ataluren patient HA HB due nonsense mutation . The main purpose study understand whether ataluren safely increase FVIII/FIX activity level .</brief_summary>
	<brief_title>Study Ataluren ( PTC124® ) Hemophilia A B</brief_title>
	<detailed_description>In study , patient hemophilia A hemophilia B due nonsense mutation treat investigational drug call ataluren ( PTC124 ) . Evaluation procedure determine patient qualifies study perform within 14 day prior start treatment . Eligible patient elect enroll study participate 28-day treatment period . Within 28-day period , ataluren ( PTC124 ) treatment take 3 time per day meal 14 day dose 10 mg/kg ( morning ) , 10 mg/kg ( midday ) 20 mg/kg ( even ) ; interval approximately 14 day without treatment . During study , ataluren ( PTC124 ) efficacy , safety , pharmacokinetics evaluate periodically measurement FVIII/FIX activity inhibitor level , blood test , urinalysis .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Ability provide write informed consent Age ≥18 year Presence nonsense mutation sole diseasecausing mutation FVIII FIX gene At least 20 prior treatment FVIII FIX concentrate Willingness ability comply schedule visit , drug administration plan , study restriction , study procedure Known hypersensitivity ingredient excipients study drug Any history prior antiFVIII/FIX inhibitor Unable unwilling forego prophylactic FVIII/FIX concentrate use screen onstudy period ( Note : Patients allow use FVIII/FIX concentrate treatment bleed episode study )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>Hemophilia B</keyword>
	<keyword>Factor VIII</keyword>
	<keyword>Factor IX</keyword>
	<keyword>FVIII</keyword>
	<keyword>FIX</keyword>
	<keyword>Nonsense mutation</keyword>
	<keyword>Premature stop codon</keyword>
	<keyword>HA</keyword>
	<keyword>HB</keyword>
	<keyword>PTC124</keyword>
	<keyword>Ataluren</keyword>
</DOC>